Matrix metalloproteases role in bowel inflammation and inflammatory bowel disease: An up to date review

Inflammatory Bowel Diseases

Volumn 20, Issue 12, 2014, Pages 2379-2393

  O'Shea, Nuala R ^a,b   Smith, Andrew M ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Crohn's disease; Extracellular matrix; Inflammatory bowel disease; Intestine; Matrix metalloprotease; Ulcerative colitis

Indexed keywords

ALPHA 2 MACROGLOBULIN; COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 20; MATRIX METALLOPROTEINASE 21; MATRIX METALLOPROTEINASE 23; MATRIX METALLOPROTEINASE 24; MATRIX METALLOPROTEINASE 25; MATRIX METALLOPROTEINASE 26; MATRIX METALLOPROTEINASE 27; MATRIX METALLOPROTEINASE 28; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; BACTERICIDAL ACTIVITY; CELL MIGRATION; COLITIS; DISEASE MARKER; ENTERITIS; EPITHELIZATION; EXTRACELLULAR MATRIX; FISTULA; GASTROINTESTINAL TRACT; GENE EXPRESSION; GENETIC VARIABILITY; HOMEOSTASIS; HUMAN; ILEITIS; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; INTESTINAL FIBROSIS; LEUKOCYTE; MESENCHYME CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PYODERMA GANGRENOSUM; RECURRENT DISEASE; REVIEW; TISSUE INJURY; TISSUE REPAIR; TURNOVER TIME; WOUND HEALING; ANIMAL; ENZYMOLOGY; METABOLISM; MOUSE; PATHOPHYSIOLOGY;

ANIMALS; HUMANS; INFLAMMATORY BOWEL DISEASES; MATRIX METALLOPROTEINASES; MICE;

EID: 84925705665     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000163     Document Type: Review

References (163)

1. Haro H, Crawford HC, Fingleton B, et al. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest. 2000;105:143-150. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=377426&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
2. Schönbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol. 1998;161:3340-3346. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9759850. Accessed June 2, 2014.
3. Ito A, Mukaiyama A, Itoh Y, et al. Degradation of interleukin 1beta by matrix metalloproteinases. J Biol Chem. 1996;271:14657-14660. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8663297. Accessed June 2, 2014.
4. McQuibban GA, Butler GS, Gong JH, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem. 2001;276:43503-43508. Available at: http://www.ncbi. nlm.nih.gov/pubmed/11571304. Accessed June 2, 2014.
5. McQuibban GA, Gong JH, Wong JP, et al. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood. 2002;100:1160-1167. Available at: http://www.ncbi.nlm.nih. gov/pubmed/12149192. Accessed June 2, 2014.
6. Van Den Steen PE, Wuyts A, Husson SJ, et al. Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/ CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur J Biochem. 2003;270:3739-3749. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12950257. Accessed June 2, 2014.
7. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol. 2001;13:534-540. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11544020. Accessed June 2, 2014.
8. Nissinen L, Kähäri VM. Matrix metalloproteinases in inflammation. Biochim Biophys Acta. 2014;1840:2571-2580. Available at: http://www. ncbi.nlm.nih.gov/pubmed/24631662. Accessed June 2, 2014.
9. Kis-Toth K, Bacskai I, Gogolak P, et al. Monocyte-derived dendritic cell subpopulations use different types of matrix metalloproteinases inhibited by GM6001. Immunobiology. 2013;218:1361-1369. Available at: http:// www.ncbi.nlm.nih.gov/pubmed/23870824. Accessed June 2, 2014.
10. McKleroy W, Lee TH, Atabai K. Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis. Am J Physiol Lung Cell Mol Physiol. 2013;304:L709-L721. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3680761&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
11. Zhao H, Dong Y, Tian X, et al. Matrix metalloproteinases contribute to kidney fibrosis in chronic kidney diseases. World J Nephrol. 2013;2: 84-89. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3832915&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
12. Eck SM, Blackburn JS, Schmucker AC, et al. Matrix metalloproteinase and G protein coupled receptors: co-conspirators in the pathogenesis of autoimmune disease and cancer. J Autoimmun. 33:214-221. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2783549&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
13. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434. Available at: http://www. ncbi.nlm.nih.gov/pubmed/17653185. Accessed May 24, 2014.
14. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008;40:955-962. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2574810&tool=pmcentrez&rendertype=abstract. Accessed May 23, 2014.
15. Thompson AI, Lees CW. Genetics of ulcerative colitis. Inflamm Bowel Dis. 2011;17:831-848. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/21319274. Accessed May 24, 2014.
16. Noble CL, Abbas AR, Cornelius J, et al. Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis. Gut. 2008;57:1398-1405. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/18523026. Accessed February 25, 2013.
17. Noble CL, Abbas AR, Lees CW, et al. Characterization of intestinal gene expression profiles in Crohn's disease by genome-wide microarray analysis. Inflamm Bowel Dis. 2010;16:1717-1728. Available at: http://www. ncbi.nlm.nih.gov/pubmed/20848455. Accessed June 5, 2014.
18. Baugh MD, Perry MJ, Hollander AP, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology. 1999;117:814-822. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 10500063. Accessed June 2, 2014.
19. Bailey CJ, Hembry RM, Alexander A, et al. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. Journal of Clinical Pathology. 1994;47:113-116. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=501822&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
20. von Lampe B, Barthel B, Coupland SE, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut. 2000;47:63-73. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1727961&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
21. de Bruyn M, Machiels K, Vandooren J, et al. Infliximab restores the dysfunctional matrix remodeling protein and growth factor gene expression in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:339-352. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 24378596. Accessed May 28, 2014.
22. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562-573. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16405877. Accessed June 2, 2014.
23. Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A. 1990;87:5578-5582. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=54368&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
24. Murphy G, Knäuper V. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain?. Matrix Biol. 1997;15:511-518. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9138283. Accessed June 2, 2014.
25. Vandooren J, Van den Steen PE, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol. 2013;48:222-272. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23547785. Accessed June 2, 2014.
26. Cao J, Sato H, Takino T, et al. The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase A activation. J Biol Chem. 1995;270:801-805. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7822314. Accessed June 2, 2014.
27. Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci U S A. 1962;48:1014-1022. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=220898&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
28. Hooper NM. Families of zinc metalloproteases. FEBS Lett. 1994;354:1-6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7957888. Accessed June 2, 2014.
29. Grant GA, Goldberg GI, Wilhelm SM, et al. Activation of extracellular matrix metalloproteases by proteases and organomercurials. Matrix Suppl. 1992;1:217-223. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/1480030. Accessed June 2, 2014.
30. Harper E, Bloch KJ, Gross J. The zymogen of tadpole collagenase. Biochemistry. 1971;10:3035-3041. Available at: http://www.ncbi.nlm. nih.gov/pubmed/4331330. Accessed June 2, 2014.
31. Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature. 1995;375:244-247. Available at: http:// www.ncbi.nlm.nih.gov/pubmed/7746327. Accessed June 2, 2014.
32. Lohi J, Wilson CL, Roby JD, et al. Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J Biol Chem. 2001;276:10134-10144. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11121398. Accessed June 2, 2014.
33. Medina C, Radomski MW. Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther. 2006;318:933-938. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16644899. Accessed June 2, 2014.
34. Murphy G, Cockett MI, Stephens PE, et al. Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J. 1987;248:265-268. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1148528&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
35. Knäuper V, Wilhelm SM, Seperack PK, et al. Direct activation of human neutrophil procollagenase by recombinant stromelysin. Biochem J. 1993; 295(pt 2):581-586. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1134920&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
36. Goldberg GI, Strongin A, Collier IE, et al. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem. 1992;267: 4583-4591. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 1311314. Accessed June 2, 2014.
37. Fridman R, Toth M, Peña D, et al. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res. 1995;55:2548-2555. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7780967. Accessed June 2, 2014.
38. Lehti K, Lohi J, Valtanen H, et al. Proteolytic processing of membranetype-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. Biochem J. 1998;334(pt 2):345-353. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1219696&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
39. Knäuper V, Will H, López-Otin C, et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem. 1996;271:17124-17131. Available at: http://www.ncbi. nlm.nih.gov/pubmed/8663255. Accessed June 2, 2014.
40. Murphy G, Stanton H, Cowell S, et al. Mechanisms for pro matrix metalloproteinase activation. APMIS. 1999;107:38-44. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10190278. Accessed June 2, 2014.
41. Tam EM, Wu YI, Butler GS, et al. Collagen binding properties of the membrane type-1 matrix metalloproteinase (MT1-MMP) hemopexin C domain. The ectodomain of the 44-kDa autocatalytic product of MT1-MMP inhibits cell invasion by disrupting native type I collagen cleavage. J Biol Chem. 2002;277:39005-39014. Available at: http://www.ncbi. nlm.nih.gov/pubmed/12145314. Accessed June 2, 2014.
42. Makowski GS, Ramsby ML. Autoactivation profiles of calciumdependent matrix metalloproteinase-2 and-9 in inflammatory synovial fluid: effect of pyrophosphate and bisphosphonates. Clin Chim Acta. 2005;358:182-191. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 15921672. Accessed June 2, 2014.
43. Kirkegaard T, Hansen A, Bruun E, et al. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut. 2004;53:701-709. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1774029&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
44. Ravi A, Garg P, Sitaraman SV. Matrix metalloproteinases in inflammatory bowel disease: boon or a bane? Inflamm Bowel Dis. 2007;13:97-107. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17206645. Accessed February 25, 2013.
45. Castaneda FE, Walia B, Vijay-Kumar M, et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology. 2005;129:1991-2008. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16344067. Accessed February 25, 2013.
46. Mimura T, Bateman AC, Lee RL, et al. Up-regulation of collagen and tissue inhibitors of matrix metalloproteinase in colonic diverticular disease. Dis Colon Rectum. 2004;47:371-378; discussion 378-379. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14991500. Accessed June 2, 2014.
47. Speake WJ, Dean RA, Kumar A, et al. Radiation induced MMP expression from rectal cancer is short lived but contributes to in vitro invasion. Eur J Surg Oncol. 2005;31:869-874. Available at: http://www.ncbi.nlm. nih.gov/pubmed/16081236. Accessed June 2, 2014.
48. Bister V, Salmela MT, Heikkilä P, et al. Matrilysins-1 and-2 (MMP-7 and-26) and metalloelastase (MMP-12), unlike MMP-19, are upregulated in necrotizing enterocolitis. J Pediatr Gastroenterol Nutr. 2005;40:60-66. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 15625428. Accessed June 2, 2014.
49. Medina C, Santana A, Paz-Cabrera MC, et al. Increased activity and expression of gelatinases in ischemic colitis. Dig Dis Sci. 2006;51: 2393-2399. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 17089188. Accessed June 2, 2014.
50. Hasty KA, Pourmotabbed TF, Goldberg GI, et al. Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases. J Biol Chem. 1990;265:11421-11424. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2164002. Accessed June 2, 2014.
51. Pugin J, Widmer MC, Kossodo S, et al. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol. 1999;20:458-464. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10030844. Accessed June 2, 2014.
52. Pender SLF, Li CKF, Di Sabatino A, et al. Role of macrophage metalloelastase in gut inflammation. Ann N Y Acad Sci. 2006;1072:386-388. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17057219. Accessed June 2, 2014.
53. Ito A, Sato T, Iga T, et al. Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitor of metalloproteinases (TIMP) production by human fibroblasts. FEBS Lett. 1990;269:93-95. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2167246. Accessed June 2, 2014.
54. Kim KC, Lee CH. MAP kinase activation is required for the MMP-9 induction by TNF-stimulation. Arch Pharm Res. 2005;28:1257-1262. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16350852. Accessed June 2, 2014.
55. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463-516. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2792593&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
56. Gan X, Wong B, Wright SD, et al. Production of matrix metalloproteinase-9 in CaCO-2 cells in response to inflammatory stimuli. J Interferon Cytokine Res. 2001;21:93-98. Available at: http://www. ncbi.nlm.nih.gov/pubmed/11244573. Accessed June 2, 2014.
57. Nee LE, McMorrow T, Campbell E, et al. TNF-alpha and IL-1betamediated regulation of MMP-9 and TIMP-1 in renal proximal tubular cells. Kidney Int. 2004;66:1376-1386. Available at: http://www.ncbi. nlm.nih.gov/pubmed/15458430. Accessed June 2, 2014.
58. López-Boado YS, Wilson CL, Hooper LV, et al. Bacterial exposure induces and activates matrilysin in mucosal epithelial cells. J Cell Biol. 2000;148:1305-1315. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2174301&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
59. Kim H, Koh G. Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NF-kappaB-dependent pathway. Biochem Biophys Res Commun. 2000;269:401-405. Available at: http://www. ncbi.nlm.nih.gov/pubmed/10708565. Accessed June 2, 2014.
60. Lai WC, Zhou M, Shankavaram U, et al. Differential regulation of lipopolysaccharide-induced monocyte matrix metalloproteinase (MMP)-1 and MMP-9 by p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. J Immunol. 2003;170:6244-6249. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12794156. Accessed June 2, 2014.
61. Rhee JW, Lee KW, Kim D, et al. NF-kappaB-dependent regulation of matrix metalloproteinase-9 gene expression by lipopolysaccharide in a macrophage cell line RAW 264.7. J Biochem Mol Biol. 2007;40: 88-94. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17244487. Accessed June 2, 2014.
62. Tomita T, Fujii M, Tokumaru Y, et al. Granulocyte-macrophage colonystimulating factor upregulates matrix metalloproteinase-2 (MMP-2) and membrane type-1 MMP (MT1-MMP) in human head and neck cancer cells. Cancer Lett. 2000;156:83-91. Available at: http://www.ncbi.nlm. nih.gov/pubmed/10840163. Accessed June 2, 2014.
63. Gutschalk CM, Yanamandra AK, Linde N, et al. GM-CSF enhances tumor invasion by elevated MMP-2,-9, and-26 expression. Cancer Med. 2013;2:117-129. Available at: http://www.pubmedcentral.nih. gov/articlerender.fcgi?artid=3639651&tool=pmcentrez&rendertype= abstract. Accessed June 2, 2014.
64. Edwards DR, Murphy G, Reynolds JJ, et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J. 1987;6:1899-1904. Available at: http://www.pubmedcentral. nih.gov/articlerender.fcgi?artid=553574&tool=pmcentrez&rendertype= abstract. Accessed June 2, 2014.
65. Kim HS, Shang T, Chen Z, et al. TGF-beta1 stimulates production of gelatinase (MMP-9), collagenases (MMP-1,-13) and stromelysins (MMP-3,-10,-11) by human corneal epithelial cells. Exp Eye Res. 2004;79:263-274. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 15325573. Accessed June 2, 2014.
66. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol. 2007;211:19-26. Available at: http://www.ncbi.nlm. nih.gov/pubmed/17167774. Accessed June 2, 2014.
67. Sottrup-Jensen L, Birkedal-Hansen H. Human fibroblast collagenasealpha-macroglobulin interactions. Localization of cleavage sites in the bait regions of five mammalian alpha-macroglobulins. J Biol Chem. 1989;264:393-401. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 2462561. Accessed June 2, 2014.
68. Garg P, Rojas M, Ravi A, et al. Selective ablation of matrix metalloproteinase-2 exacerbates experimental colitis: contrasting role of gelatinases in the pathogenesis of colitis. J Immunol. 2006;177: 4103-4112. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 16951375. Accessed February 25, 2013.
69. Pirilä E, Ramamurthy NS, Sorsa T, et al. Gelatinase A (MMP-2), collagenase-2 (MMP-8), and laminin-5 gamma2-chain expression in murine inflammatory bowel disease (ulcerative colitis). Dig Dis Sci. 2003;48:93-98. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 12645796. Accessed June 2, 2014.
70. Naito Y, Takagi T, Kuroda M, et al. An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice. Inflamm Res. 2004;53:462-468. Available at: http:// www.ncbi.nlm.nih.gov/pubmed/15550999. Accessed June 2, 2014.
71. Koller FL, Dozier EA, Nam KT, et al. Lack of MMP10 exacerbates experimental colitis and promotes development of inflammationassociated colonic dysplasia. Lab Invest. 2012;92:1749-1759. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3510327&tool= pmcentrez&rendertype=abstract. Accessed June 2, 2014.
72. Vandenbroucke RE, Dejonckheere E, Van Hauwermeiren F, et al. Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF. EMBO Mol Med. 2013;5:932-948. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3721470&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
73. Garg P, Vijay-Kumar M, Wang L, et al. Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis. Am J Physiol Gastrointestin Liver Physiol. 2009;296:G175-G184. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2643910&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
74. te Velde AA, de Kort F, Sterrenburg E, et al. Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:325-330. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17206675. Accessed June 2, 2014.
75. Rodrigues DM, Sousa AJ, Hawley SP, et al. Matrix metalloproteinase 9 contributes to gut microbe homeostasis in a model of infectious colitis. BMC Microbiol. 2012;12:105. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3676156&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
76. Handley SA, Miller VL. General and specific host responses to bacterial infection in Peyer's patches: a role for stromelysin-1 (matrix metalloproteinase-3) during Salmonella enterica infection. Mol Microbiol. 2007;64:94-110. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/17376075. Accessed June 2, 2014.
77. Santana A, Medina C, Paz-Cabrera MC, et al. Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice. World J Gastroenterol. 2006;12:6464-6472. Available at: http:// www.ncbi.nlm.nih.gov/pubmed/17072979. Accessed February 25, 2013.
78. Mao JW, He XM, Tang HY, et al. Protective role of metalloproteinase inhibitor (AE-941) on ulcerative colitis in rats. World J Gastroenterol. 2012;18:7063-7069. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3531695&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
79. Seifert WF, Wobbes T, Hendriks T. Divergent patterns of matrix metalloproteinase activity during wound healing in ileum and colon of rats. Gut. 1996;39:114-119. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1383243&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
80. Oehlers SH, Flores MV, Okuda KS, et al. A chemical enterocolitis model in zebrafish larvae that is dependent on microbiota and responsive to pharmacological agents. Dev Dyn. 2011;240:288-298. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21181946. Accessed June 2, 2014.
81. Hanifeh M, Rajamäki MM, Mäkitalo L, et al. Identification of matrix metalloproteinase-2 and-9 activities within intestinal mucosa of clinically healthy beagle dogs. J Vet Med Sci. 2014. Available at: http://www. ncbi.nlm.nih.gov/pubmed/24748420. Accessed June 2, 2014.
82. Li CKF, Pender SLF, Pickard KM, et al. Impaired immunity to intestinal bacterial infection in stromelysin-1 (matrix metalloproteinase-3)-deficient mice. J Immunol. 2004;173:5171-5179. Available at: http:// www.ncbi.nlm.nih.gov/pubmed/15470062. Accessed February 25, 2013.
83. Swee M, Wilson CL, Wang Y, et al. Matrix metalloproteinase-7 (matrilysin) controls neutrophil egress by generating chemokine gradients. J Leukoc Biol. 2008;83:1404-1412. Available at: http://www.ncbi.nlm. nih.gov/pubmed/18334539. Accessed June 2, 2014.
84. Wilson CL, Ouellette AJ, Satchell DP, et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science. 1999;286:113-117. Available at: http://www.ncbi. nlm.nih.gov/pubmed/10506557. Accessed June 2, 2014.
85. Ishida K, Takai S, Murano M, et al. Role of chymase-dependent matrix metalloproteinase-9 activation in mice with dextran sodium sulfateinduced colitis. J Pharmacol Exp Ther. 2008;324:422-426. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18024785. Accessed June 2, 2014.
86. Medina C, Santana A, Paz MC, et al. Matrix metalloproteinase-9 modulates intestinal injury in rats with transmural colitis. J Leukoc Biol. 2006;79:954-962. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 16478919. Accessed June 2, 2014.
87. Liu H, Patel NR, Walter L, et al. Constitutive expression of MMP9 in intestinal epithelium worsens murine acute colitis and is associated with increased levels of proinflammatory cytokine Kc. Am J Physiol Gastrointest Liver Physiol. 2013;304:G793-G803. Available at: http://www. ncbi.nlm.nih.gov/pubmed/23471340. Accessed May 29, 2014.
88. Heimesaat MM, Dunay IR, Fuchs D, et al. The distinct roles of MMP-2 and MMP-9 in acute DSS colitis. Eur J Microbiol Immunol. 2011;1:302-310. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3918133&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
89. Tester AM, Cox JH, Connor AR, et al. LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity. PLoS One. 2007; 2:e312. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1819564&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
90. Li Q, Park PW, Wilson CL, et al. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell. 2002;111:635-646. Available at: http://www. ncbi.nlm.nih.gov/pubmed/12464176. Accessed June 2, 2014.
91. Weathington NM, van Houwelingen AH, Noerager BD, et al. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med. 2006;12:317-323. Available at: http:// www.ncbi.nlm.nih.gov/pubmed/16474398. Accessed June 4, 2014.
92. Koelink PJ, Overbeek SA, Braber S, et al. Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease. Gut. 2014;63:578-587. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/23525573. Accessed September 30, 2013.
93. Churg A, Wang RD, Tai H, et al. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factoralpha release. Am J Respir Crit Care Med. 2003;167:1083-1089. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12522030. Accessed June 3, 2014.
94. Shi J, Aono S, Lu W, et al. A novel role for defensins in intestinal homeostasis: regulation of IL-1beta secretion. J Immunol. 2007;179: 1245-1253. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 17617617. Accessed June 4, 2014.
95. Houghton AM, Hartzell WO, Robbins CS, et al. Macrophage elastase kills bacteria within murine macrophages. Nature. 2009;460:637-641. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2885871&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
96. Pal S, Schmidt AP, Peterson EM, et al. Role of matrix metalloproteinase-7 in the modulation of a Chlamydia trachomatis infection. Immunology. 2006;117:213-219. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1782213&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
97. McCarty SM, Percival SL. Proteases and delayed wound healing. Adv Wound Care (New Rochelle). 2013;2:438-447. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3842891&tool=pmcentrez&rendertype=abstract. Accessed June 3, 2014.
98. Pilcher BK, Dumin JA, Sudbeck BD, et al. The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. J Cell Biol. 1997;137:1445-1457. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2132537&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
99. Salmela MT, Pender SLF, Karjalainen-Lindsberg ML, et al. Collagenase-1 (MMP-1), matrilysin-1 (MMP-7), and stromelysin-2 (MMP-10) are expressed by migrating enterocytes during intestinal wound healing. Scand J Gastroenterol. 2004;39:1095-1104. Available at: http://www. ncbi.nlm.nih.gov/pubmed/15545168. Accessed May 26, 2014.
100. Gill SE, Parks WC. Metalloproteinases and their inhibitors: regulators of wound healing. Int J Biochem Cell Biol. 2008;40:1334-1347. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2746915&tool=pmcentrez&rendertype=abstract. Accessed June 3, 2014.
101. Krampert M, Bloch W, Sasaki T, et al. Activities of the matrix metalloproteinase stromelysin-2 (MMP-10) in matrix degradation and keratinocyte organization in wounded skin. Mol Biol Cell. 2004;15: 5242-5254. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=532007&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
102. Hayden DM, Forsyth C, Keshavarzian A. The role of matrix metalloproteinases in intestinal epithelial wound healing during normal and inflammatory states. J Surg Res. 2011;168:315-324. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20655064. Accessed June 2, 2014.
103. McGuire JK, Li Q, Parks WC. Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am J Pathol. 2003;162:1831-1843. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1868120&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
104. Bamba S, Andoh A, Yasui H, et al. Matrix metalloproteinase-3 secretion from human colonic subepithelial myofibroblasts: role of interleukin-17. J Gastroenterol. 2003;38:548-554. Available at: http://www.ncbi.nlm. nih.gov/pubmed/12825130. Accessed June 3, 2014.
105. Bullard KM, Mudgett J, Scheuenstuhl H, et al. Stromelysin-1-deficient fibroblasts display impaired contraction in vitro. J Surg Res. 1999;84:31-34. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10334885. Accessed June 2, 2014.
106. Bullard KM, Lund L, Mudgett JS, et al. Impaired wound contraction in stromelysin-1-deficient mice. Ann Surg. 1999;230:260-265. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1420869&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
107. Saarialho-Kere UK, Vaalamo M, Puolakkainen P, et al. Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol. 1996;148:519-526. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1861683&tool=pmcentrez&rendertype=abstract. Accessed June 3, 2014.
108. Stumpf M, Cao W, Klinge U, et al. Reduced expression of collagen type I and increased expression of matrix metalloproteinases 1 in patients with Crohn's disease. J Invest Surg. 18:33-38. Available at: http://www.ncbi. nlm.nih.gov/pubmed/15804950. Accessed June 3, 2014.
109. Jimbo K, Ohtsuka Y, Kojima Y, et al. Increased expression of CXCR3 axis components and MMPs in pediatric IBD patients. Pediatr Int. 2014. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24750209. Accessed June 3, 2014.
110. Louis E, Ribbens C, Godon A, et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol. 2000;120:241-246. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1905637&tool=pmcentrez&rendertype=abstract. Accessed June 3, 2014.
111. Matsuno K, Adachi Y, Yamamoto H, et al. The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis. J Gastroenterol. 2003;38:348-354. Available at: http:// www.ncbi.nlm.nih.gov/pubmed/12743774. Accessed June 3, 2014.
112. Rath T, Roderfeld M, Halwe JM, et al. Cellular sources of MMP-7, MMP-13 and MMP-28 in ulcerative colitis. Scand J Gastroenterol. 2010;45:1186-1196. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/20568971. Accessed June 3, 2014.
113. Meijer MJW, Mieremet-Ooms MAC, van Hogezand RA, et al. Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol. 2007;13:2960-2966. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17589947. Accessed June 3, 2014.
114. Meijer MJ, Mieremet-Ooms MAC, van Duijn W, et al. Effect of the antitumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:200-210. Available at: http://www. ncbi.nlm.nih.gov/pubmed/17206679. Accessed June 3, 2014.
115. Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P, et al. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol. 1998;152:1005-1014. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1858229&tool=pmcentrez&rendertype=abstract. Accessed June 3, 2014.
116. Mäkitalo L, Kolho KL, Karikoski R, et al. Expression profiles of matrix metalloproteinases and their inhibitors in colonic inflammation related to pediatric inflammatory bowel disease. Scand J Gastroenterol. 2010;45: 862-871. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20367198. Accessed June 3, 2014.
117. Vizoso FJ, González LO, Corte MD, et al. Collagenase-3 (MMP-13) expression by inflamed mucosa in inflammatory bowel disease. Scand J Gastroenterol. 2006;41:1050-1055. Available at: http://www.ncbi. nlm.nih.gov/pubmed/16938718. Accessed June 3, 2014.
118. Bister VO, Salmela MT, Karjalainen-Lindsberg ML, et al. Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-28, in normal and inflamed intestine and colon cancer. Dig Dis Sci. 2004;49:653-661. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/15185874. Accessed June 3, 2014.
119. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12131607. Accessed June 4, 2014.
120. Latella G, Sferra R, Speca S, et al. Can we prevent, reduce or reverse intestinal fibrosis in IBD? Eur Rev Med Pharmacol Sci. 2013;17:1283-1304. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23740440. Accessed June 4, 2014.
121. Rieder F, Fiocchi C. Intestinal fibrosis in IBD-a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol. 2009;6:228-235. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19347014. Accessed May 28, 2014.
122. Di Sabatino A, Jackson CL, Pickard KM, et al. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut. 2009;58:777-789. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19201776. Accessed June 4, 2014.
123. McKaig BC, Hughes K, Tighe PJ, et al. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol. 2002;282:C172-C182. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11742810. Accessed June 4, 2014.
124. Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology. 1996;110:975-984. Available at: http://www. ncbi.nlm.nih.gov/pubmed/8613031. Accessed June 4, 2014.
125. Imai K, Hiramatsu A, Fukushima D, et al. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J. 1997;322(pt 3):809-814. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1218259&tool=pmcentrez&rendertype=abstract. Accessed June 4, 2014.
126. Warnaar N, Hofker HS, Maathuis MHJ, et al. Matrix metalloproteinases as profibrotic factors in terminal ileum in Crohn's disease. Inflamm Bowel Dis. 2006;12:863-869. Available at: http://www.ncbi.nlm.nih. gov/pubmed/16954805. Accessed June 4, 2014.
127. Pender SLF, Croucher PJP, Mascheretti S, et al. Transmission disequilibrium test of stromelysin-1 gene variation in relation to Crohn's disease. J MedGenet. 2004;41:e112. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1735882&tool=pmcentrez&rendertype=abstract. Accessed June 4, 2014.
128. Bataille F, Klebl F, Rümmele P, et al. Morphological characterisation of Crohn's disease fistulae. Gut. 2004;53:1314-1321. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1774207&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
129. Lewis RT, Maron DJ. Efficacy and complications of surgery for Crohn's disease. Gastroenterol Hepatol (N Y). 2010;6:587-596. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2976865&tool=pmcentrez&rendertype=abstract. Accessed June 5, 2014.
130. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990;99:956-963. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2394349. Accessed June 5, 2014.
131. Meijer MJ, Mieremet-Ooms MAC, Sier CFM, et al. Matrix metalloproteinases and their tissue inhibitors as prognostic indicators for diagnostic and surgical recurrence in Crohn's disease. Inflamm Bowel Dis. 2009;15: 84-92. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18634035. Accessed June 5, 2014.
132. Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. J Crohn Colitis. 2014. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/24636140. Accessed June 4, 2014.
133. Renò F, Rocchetti V, Migliario M, et al. Nicotine modulates gelatinase B (MMP-9) and epilysin (MMP-28) expression in reconstituted human oral epithelium. J Oral Pathol Med. 2011;40:33-36. Available at: http:// www.ncbi.nlm.nih.gov/pubmed/20923448. Accessed June 5, 2014.
134. Renò F, Rocchetti V, Migliario M, et al. Chronic exposure to cigarette smoke increases matrix metalloproteinases and filaggrin mRNA expression in oral keratinocytes: role of nicotine stimulation. Oral Oncol. 2011; 47:827-830. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 21723775. Accessed June 5, 2014.
135. Monstad I, Hovde O, Solberg IC, et al. Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies. Ann Gastroenterol. 2014;27:95-104. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3982647&tool=pmcentrez&rendertype=abstract. Accessed June 5, 2014.
136. Stocchi L, Pemberton JH. Pouch and pouchitis. Gastroenterol Clin North Am. 2001;30:223-241. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/11394032. Accessed June 5, 2014.
137. Hahnloser D, Pemberton JH, Wolff BG, et al. Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Br J Surg. 2007;94:333-340. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/17225210. Accessed June 5, 2014.
138. Mäkitalo L, Piekkala M, Ashorn M, et al. Matrix metalloproteinases in the restorative proctocolectomy pouch of pediatric ulcerative colitis. World J Gastroenterol. 2012;18:4028-4036. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3420000&tool=pmcentrez&rendertype=abstract. Accessed June 3, 2014.
139. Stallmach A, Chan CC, Ecker KW, et al. Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut. 2000;47:415-422. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1728023&tool=pmcentrez&rendertype=abstract. Accessed June 5, 2014.
140. Agarwal A, Andrews JM. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Alimen Pharmacol Ther. 2013;38:563-572. Available at: http://www.ncbi.nlm.nih. gov/pubmed/23914999. Accessed June 5, 2014.
141. Bister V, Mäkitalo L, Jeskanen L, et al. Expression of MMP-9, MMP-10 and TNF-alpha and lack of epithelial MMP-1 and MMP-26 characterize pyoderma gangrenosum. J Cutan Pathol. 2007;34:889-898. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18001410. Accessed June 3, 2014.
142. Marzano AV, Cugno M, Trevisan V, et al. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol. 2010;162:100-107. Available at: http:// www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2990935&tool= pmcentrez&rendertype=abstract. Accessed June 5, 2014.
143. Gao Q, Meijer MJW, Schlüter UG, et al. Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and-9 in Crohn's disease. Inflamm Bowel Dis. 2007;13:693-702. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17243139. Accessed June 3, 2014.
144. Mäkitalo L, Sipponen T, Kärkkäinen P, et al. Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values. Int J Colorectal Dis. 2009;24:1157-1167. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/19652986. Accessed June 3, 2014.
145. Annaházi A, Molnár T, Farkas K, et al. Fecal MMP-9: a new noninvasive differential diagnostic and activity marker in ulcerative colitis. Inflamm Bowel Dis. 2013;19:316-320. Available at: http://www.ncbi.nlm. nih.gov/pubmed/22550024. Accessed June 5, 2014.
146. Däbritz J, Musci J, Foell D. Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome. World J Gastroenterol. 2014;20: 363-375. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3923012&tool=pmcentrez&rendertype=abstract. Accessed June 2, 2014.
147. Kolho KL, Sipponen T, Valtonen E, et al. Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease. Int J Colorectal Dis. 2014;29:43-50. Available at: http://www. ncbi.nlm.nih.gov/pubmed/24077667. Accessed June 5, 2014.
148. Manfredi MA, Zurakowski D, Rufo PA, et al. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14:1091-1096. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 18338781. Accessed June 5, 2014.
149. Kofla-Dubacz A, Matusiewicz M, Krzesiek E, et al. Metalloproteinase-3 and-9 as novel markers in the evaluation of ulcerative colitis activity in children. Adv Clin Exp Med. 23:103-110. Available at: http://www.ncbi. nlm.nih.gov/pubmed/24596011. Accessed June 5, 2014.
150. Kofla-Dlubacz A, Matusiewicz M, Krzystek-Korpacka M, et al. Correlation of MMP-3 and MMP-9 with Crohn's disease activity in children. Dig Dis Sci. 2012;57:706-712. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3282895&tool=pmcentrez&rendertype=abstract. Accessed June 5, 2014.
151. Faubion WA, Fletcher JG, O'Byrne S, et al. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging. Am J Gastroenterol. 2013;108:1891-1900. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24126633. Accessed June 4, 2014.
152. Wiercinska-Drapalo A, Jaroszewicz J, Flisiak R, et al. Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity. World J Gastroenterol. 2003;9: 2843-2845. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 14669348. Accessed June 5, 2014.
153. Altadill A, Eiró N, González LO, et al. Comparative analysis of the expression of metalloproteases and their inhibitors in resected crohn's disease and complicated diverticular disease. Inflamm Bowel Dis. 2012; 18:120-130. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 21438097. Accessed June 5, 2014.
154. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006;55:205-211. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1856500&tool=pmcentrez&rendertype=abstract. Accessed May 27, 2014.
155. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59-65. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3779803&tool=pmcentrez&rendertype=abstract. Accessed May 23, 2014.
156. Medina C, Santana A, Llopis M, et al. Induction of colonic transmural inflammation by Bacteroides fragilis: implication of matrix metalloproteinases. Inflamm Bowel Dis. 2005;11:99-105. Available at: http://www. ncbi.nlm.nih.gov/pubmed/15677902. Accessed June 5, 2014.
157. Steck N, Hoffmann M, Sava IG, et al. Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation. Gastroenterology. 2011;141:959-971. Available at: http://www. ncbi.nlm.nih.gov/pubmed/21699778. Accessed June 5, 2014.
158. Ye YN, Liu ES-L, Shin VY, et al. Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammationassociated colonic tumorigenesis by cigarette smoking. Toxicology. 2004;203:179-188. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 15363593. Accessed June 5, 2014.
159. Sykes AP, Bhogal R, Brampton C, et al. The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease. Alimen Pharmacol Ther. 1999;13:1535-1542. Available at: http://www.ncbi.nlm.nih. gov/pubmed/10571613. Accessed June 5, 2014.
160. Di Sebastiano P, di Mola FF, Artese L, et al. Beneficial effects of Batimastat (BB-94), a matrix metalloproteinase inhibitor, in rat experimental colitis. Digestion. 2001;63:234-239. Available at: http://www.ncbi.nlm. nih.gov/pubmed/11435723. Accessed June 5, 2014.
161. Acharya MR, Venitz J, Figg WD, et al. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist Updat. 2004;7:195-208. Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 15296861. Accessed May 28, 2014.
162. Dormán G, Cseh S, Hajdú I, et al. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs. 2010;70:949-964. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/20481653. Accessed June 3, 2014.
163. Sela-Passwell N, Kikkeri R, Dym O, et al. Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential. Nat Med. 2012;18:143-147. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22198278. Accessed June 5, 2014.